ANIP · ISSUER CIK 1023024
ANI PHARMACEUTICALS INC
Between Aug 1, 2026 and Oct 29, 2026, 6 ANI PHARMACEUTICALS INC insiders reported $0.00 of open-market purchases and $2.0M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 9 of 10 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$2.0MInsider selling
−$2.0MNet open-market
Oct 16, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 202618:50 | Oct 15, 2026 | ANIP | PRESIDENT & CEO, Director | S · Sell10b5-1 | $71.89 | −5,400 | 333,689 | -2% | −$388K | ||
| Oct 13, 202620:47 | Oct 13, 2026 | ANIP | SR. VP, GENERAL COUNSEL & SEC. | S · Sell10b5-1 | $73.59 | −500 | 73,424 | -1% | −$37K | ||
| Sep 30, 202616:52 | Sep 29, 2026 | ANIP | SVP & CFO | S · Sell10b5-1 | $73.00 | −2,850 | 168,993 | -2% | −$208K | ||
| Sep 16, 202616:20 | Sep 15, 2026 | ANIP | PRESIDENT & CEO, Director | S · Sell10b5-1 | $71.00 | −5,400 | 339,089 | -2% | −$383K | ||
| Sep 14, 202620:57 | Sep 11, 2026 | ANIP | Director | S · Sell10b5-1 | $71.53 | −1,000 | 26,762 | -4% | −$72K | ||
| Sep 14, 202620:56 | Sep 14, 2026 | ANIP | SR. VP, GENERAL COUNSEL & SEC. | S · Sell10b5-1 | $70.79 | −500 | 73,924 | -1% | −$35K | ||
| Sep 1, 202618:18 | Aug 31, 2026 | ANIP | SVP & CFO | S · Sell10b5-1 | $72.80 | −2,850 | 171,843 | -2% | −$207K | ||
| Aug 27, 202616:21 | Aug 19, 2026 | ANIP | Director | A · GrantLate 8d | — | +6,662 | 6,662 | New | — | ||
| Aug 26, 202618:15 | Aug 25, 2026 | ANIP | PRESIDENT & CEO, Director | S · Sell10b5-1 | $74.30 | −5,400 | 344,489 | -2% | −$401K | ||
| Aug 13, 202616:32 | Aug 13, 2026 | ANIP | SR. VP, GENERAL COUNSEL & SEC. | S · Sell10b5-1 | $75.48 | −500 | 74,424 | -1% | −$38K | ||
| Aug 11, 202620:57 | Aug 10, 2026 | ANIP | SVP, GENERICS | S · Sell | $77.00 | −3,162 | 75,534 | -4% | −$243K |